Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capricor Therapeutics

14.23
+1.057.97%
Post-market: 14.590.3600+2.53%19:59 EDT
Volume:2.51M
Turnover:35.06M
Market Cap:650.42M
PE:-10.02
High:14.35
Open:13.26
Low:12.80
Close:13.18
Loading ...

Capricor Therapeutics Price Target Maintained With a $30.00/Share by Cantor Fitzgerald

Dow Jones
·
20 Mar

Q4 2024 Capricor Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
20 Mar

Stock Track | Capricor Therapeutics Soars 6.46% Pre-Market on Strong Q4 Results, Analyst Optimism, and Pipeline Progress

Stock Track
·
20 Mar

Stock Track | Capricor Therapeutics (CAPR) Soars 6.38% Pre-Market on Strong Q4 Results and Analyst Optimism

Stock Track
·
20 Mar

Piper Sandler Remains a Buy on Capricor Therapeutics (CAPR)

TIPRANKS
·
20 Mar

Capricor Therapeutics Stock (CAPR) Surges on Q4 Results and Promising New Therapy

TIPRANKS
·
20 Mar

Capricor Therapeutics Reports 2024 Financial Results

TIPRANKS
·
20 Mar

Capricor Therapeutics reports Q4 EPS (16c), consensus (9c)

TIPRANKS
·
20 Mar

Capricor Therapeutics Q4 2024 GAAP EPS $(0.16) Beats $(0.26) Estimate, Sales $11.10M Beat $5.68M Estimate

Benzinga
·
20 Mar

Capricor Therapeutics Q4 Operating Expenses USD 18.8 Million

THOMSON REUTERS
·
20 Mar

Capricor Therapeutics: Available Cash, Cash Equivalents & Marketable Securities Sufficient to Cover Expenses & Capital Requirements Into 2027

THOMSON REUTERS
·
20 Mar

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
20 Mar

While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership

Simply Wall St.
·
19 Mar

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
18 Mar

Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Mar

Capricor Therapeutics announces long-term data from HOPE-2 OLE study

TIPRANKS
·
17 Mar

Capricor Therapeutics Inc: Deramiocel Was Well Tolerated With No New Safety Signals Identified

THOMSON REUTERS
·
17 Mar

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire
·
17 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

GlobeNewswire
·
11 Mar